Nacubactam is under clinical development by NacuGen Therapeutics and currently in Phase III for Complicated Intra-Abdominal Infections. According to GlobalData, Phase III drugs for Complicated Intra-Abdominal Infections have a 94% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Nacubactam’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Nacubactam overview
Nacubactam (RG6080, RO7079901) is under development for the treatment of complicated urinary tract infection, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, and complicated intra-abdominal infection due to carbapenem resistant Enterobacter ales and and gram-negative bacterial infections such as Pseudomonas aeruginosa. The drug candidate is administered through intravenous route in the form of powder for injection. It is a new molecular entity (NME) and a diazabicyclooctane beta-lactamase inhibitor.
NacuGen Therapeutics overview
NacuGen Therapeutics engaged in research, development and commercialization of novel anti-infectives including beta-lactamase inhibitors for the treatment of urinary tract infection, ventilator associated bacterial pneumonia, hospital acquired bacterial pneumonia and complicated intra-abdominal infections. The company is headquartered in Edmonton, Alberta, Canada.
For a complete picture of Nacubactam’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
